Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.78 and traded as high as $19.43. Assembly Biosciences shares last traded at $19.40, with a volume of 52,476 shares changing hands.
Assembly Biosciences Stock Up 5.4%
The firm has a market cap of $148.18 million, a P/E ratio of -3.11 and a beta of 0.64. The business has a fifty day moving average of $17.33 and a 200 day moving average of $13.78.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($2.01) by $0.84. Assembly Biosciences had a negative return on equity of 131.77% and a negative net margin of 124.15%. The business had revenue of $9.42 million for the quarter, compared to analyst estimates of $7.41 million. Research analysts expect that Assembly Biosciences, Inc. will post -6.87 EPS for the current year.
Hedge Funds Weigh In On Assembly Biosciences
Several large investors have recently modified their holdings of the stock. Gilead Sciences Inc. bought a new position in Assembly Biosciences in the 4th quarter valued at about $34,865,000. B Group Inc. bought a new position in shares of Assembly Biosciences during the fourth quarter worth approximately $799,000. Renaissance Technologies LLC lifted its holdings in Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock worth $1,495,000 after purchasing an additional 29,087 shares during the last quarter. Man Group plc acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $309,000. Finally, American Century Companies Inc. bought a new stake in Assembly Biosciences in the 1st quarter valued at $113,000. 19.92% of the stock is owned by institutional investors.
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
